Durvalumab is a type of medication known as an immune checkpoint inhibitor. It works by helping the body’s immune system recognize and attack cancer cells more effectively. In this trial, durvalumab is being used to see if it can help control or reduce the growth of various types of cancer, including pancreatic cancer, colorectal cancer, metastatic solid tumors, and soft-tissue sarcoma.

Tazemetostat is a medication that targets specific enzymes involved in the regulation of gene expression. By inhibiting these enzymes, tazemetostat can potentially slow down or stop the growth of cancer cells. In this study, it is being used in combination with durvalumab to explore its effectiveness in treating different cancer types, such as pancreatic cancer, colorectal cancer, metastatic solid tumors, and soft-tissue sarcoma.

Pancreatic Cancer – This is a type of cancer that begins in the tissues of the pancreas, an organ located behind the lower part of the stomach. It often progresses silently, with symptoms appearing only in advanced stages. As the disease advances, it may cause abdominal pain, weight loss, and jaundice. The cancer can spread to nearby organs and tissues, making it challenging to manage. It is known for its aggressive nature and resistance to many treatments.

Colorectal Cancer – This cancer affects the colon or rectum, parts of the large intestine. It typically starts as small, benign clumps of cells called polyps, which can become cancerous over time. Symptoms may include changes in bowel habits, blood in the stool, and abdominal discomfort. As it progresses, the cancer can invade deeper layers of the colon and spread to other parts of the body. Early detection through screening can help manage its progression.

Metastatic Solid Tumors – These are cancers that have spread from their original site to other parts of the body. They can originate from various organs and are characterized by their ability to invade distant tissues. The progression involves the detachment of cancer cells from the primary tumor, traveling through the bloodstream or lymphatic system. Symptoms depend on the location of metastasis and may include pain, organ dysfunction, and general weakness. The presence of a positive interferon gamma signature or tertiary lymphoid structures can influence the tumor’s behavior and response to treatment.

Soft-Tissue Sarcoma – This is a group of cancers that begin in the tissues that connect, support, or surround other structures and organs of the body. These tissues include muscle, fat, blood vessels, nerves, tendons, and the lining of the joints. The disease can develop anywhere in the body but is most common in the arms, legs, and trunk. As it progresses, it may cause a noticeable lump or swelling, pain, or limited movement in the affected area. The cancer can spread to other parts of the body, complicating treatment efforts.